Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
PPH is associated with almost 20 per cent of maternal mortality in India
This is Enzene Biosciences third biosimilar to be approved
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
The agreement will help ensure wider reach and access to patients in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
